https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-08 / Cancer Chemother. Pharmacol. 2011 May;67(5):1157-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-08 / Cancer Chemother. Pharmacol. 2011 May;67(5):1157-662010-08-08 00:00:002010-08-08 00:00:00Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / BioSystems 2010 Aug;101(2):117-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / BioSystems 2010 Aug;101(2):117-262010-08-01 00:00:002019-02-15 08:40:18Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-7042010-08-01 00:00:002019-02-15 08:52:54[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-932010-08-01 00:00:002019-02-15 08:52:58Prostate cancer as a model for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-62010-08-01 00:00:002019-02-15 09:21:42[Progress in using Newcastle disease virus for tumor therapy: a review]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-62010-08-01 00:00:002019-02-15 09:21:46[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Surgery 2010 Aug;148(2):325-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Surgery 2010 Aug;148(2):325-342010-08-01 00:00:002010-08-01 00:00:00Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-192010-07-27 00:00:002010-07-27 00:00:00Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-19 / Vaccine 2010 Jul;28(32):5153-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-19 / Vaccine 2010 Jul;28(32):5153-602010-07-19 00:00:002019-02-15 08:40:17Human myeloid dendritic cells for cancer therapy: does maturation matter?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-92010-07-14 00:00:002019-02-15 08:45:27Induction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination
